Eledon takes transplant rejection therapy to Phase III on mixed results
Eledon Pharmaceuticals’ lead asset, tegoprubart, is going to late-stage trials in kidney transplant rejection prevention, despite missing its primary efficacy …
Post
-
-
Lilly to advance alternative obesity candidate to Phase III
Eli Lilly is advancing its obesity treatment candidate, which is an alternative to glucagon-like peptide-1 receptor agonists (GLP-1RAs), to Phase …
-
Imbria randomises first subject in Phase IIb trial of nHCM therapy
Imbria Pharmaceuticals has randomised the first participant in FORTITUDE HCM, a Phase IIb trial of ninerafaxstat in symptomatic non-obstructive hypertrophic …
-
Study explores chronic health outcomes associated with polycystic ovary syndrome
The hormonal and metabolic disturbances associated with polycystic ovary syndrome (PCOS) are a risk factor for a variety of health …
-
WHO releases new report for paediatric clinical studies
The World Health Organization (WHO) has published a technical report establishing a global research agenda for paediatric clinical trials targeting …
-
WHO releases new report for paediatric clinical studies
The World Health Organization (WHO) has published a technical report establishing a global research agenda for paediatric clinical trials targeting …
-
Centessa’s stock recovers from drop on sleep drug data
Centessa Pharmaceuticals executives will be breathing a sigh of relief as its stock price recovered after a drop caused by …
-
MoonLake claws back HS potential for sonelokimab on teen trial results
MoonLake Therapeutics’ sonelokimab has posted a potential comeback in hidradenitis suppurativa (HS) following the positive results of a Phase III …
-
MMI wins IDE for surgical robotic Alzheimer’s disease study
US-based robotics company Medical Microinstruments (MMI) has obtained an investigational device exemption (IDE) from the US Food and Drug Administration …
-
Novo Nordisk’s oral Wegovy reduces cardiovascular risk factors in obesity
Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being used by the …
-
Kodiak reports follow-up outcomes from APEX study of KSI-101
Kodiak Sciences has announced follow-up outcomes from the APEX study, which showed sustained clinical effect of KSI-101 through week 20 …
-
CERo commences second cohort of AML trial
CERo Therapeutics has initiated the second cohort of its Phase I clinical trial of CER-1236 for the treatment of acute …
-
Clinical Trials Arena Excellence Awards 2025: Phesi
Phesi, a patient-centric clinical data science company serving the global biopharmaceutical industry, won the Innovation award in the 2025 Clinical …
-
Spinogenix’s ALS hopeful to advance to registrational trial
Spinogenix is progressing its lead candidate, SPG302, to a registrational trial following the positive outcome of its mid-stage study in …
-
Kamada enrols first subject in Cytogam trial for CMV infection
Kamada has enrolled the first participant in an investigator-initiated clinical trial of Cytogam (Cytomegalovirus Immune Globulin Intravenous [Human]) (CMV-IGIV) to …
